argenx SE

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles Other stock markets 11:35:00 2024-04-26 am EDT			5-day change	1st Jan Change
349.3 ^EUR	+0.90%		+3.56%	+1.69%

Apr. 17	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT
Apr. 16	Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy	CI

Argenx : argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

March 29, 2024 at 11:17 pm EST

argenx SE

argenx SE

Below you will find information from the register publication of inside information. The information has been provided by the organisation.

Registration date29 feb 2024 - 07:05

Statutory nameargenx SE

Titleargenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

Previous result

Next result

Related downloads

202402290000000005_argenx_EN_29022024.pdf(opens in a new window)

Date last update: 01 March 2024

Attachments

Original Link
Permalink

Disclaimer

arGEN-X SE published this content on 29 February 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 March 2024 04:17:40 UTC.

Latest news about argenx SE

European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 17	MT
Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy	Apr. 16	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	Apr. 04	MT
Argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease	Mar. 27	CI
Scotiabank Raises Price Target on Argenx SE to $408 From $402, Maintains Sector Perform Rating	Mar. 26	MT
Argenx Gets Japanese Regulator's Approval for Intravenous Use of Vyvgart in Primary Immune Thrombocytopenia	Mar. 26	MT
Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia	Mar. 26	CI
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Mar. 21	MT
US Futures, European Stocks Rise After Fed Maintains Outlook	Mar. 21	DJ
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading	Mar. 13	MT
Truist Securities Raises Price Target on Argenx to $440 From $370, Maintains Buy Rating	Mar. 05	MT
JMP Securities Adjusts Argenx's Price Target to $471 From $462, Keeps Market Outperform Rating	Mar. 01	MT
Baird Cuts Price Target on Argenx to $490 From $505, Maintains Outperform Rating	Mar. 01	MT
Global markets live: HP, Moncler, Snowflake, Salesforce, Duolingo...	Feb. 29
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	Feb. 29	MT
Sector Update: Health Care Stocks Advance Premarket Thursday	Feb. 29	MT
Sector Update: Health Care	Feb. 29	MT
Transcript : Argenx SE, Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Argenx Q4 Loss Widens, Revenue Increases -- Shares Down Pre-Bell	Feb. 29	MT
Argenx SE Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29	CI
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	Feb. 20	MT
Argenx Says FDA Accepted for Priority Review Supplemental BLA for Autoimmune Disease Drug Vyvgart Hytrulo	Feb. 20	MT
US FDA Accepts for Priority Review Argenx's Biologics License Application for Vyvgart Hytrulo	Feb. 20	MT
Argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy	Feb. 20	CI
Wolfe Research Starts Argenx With Peer Perform Rating	Feb. 15	MT

Chart argenx SE

Duration

Period

More charts

Company Profile

argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Annual General Meeting

Related indices

STOXX EUROPE 600 (EUR) , BEL-20

More about the company

Income Statement Evolution

More financial data

Ratings for argenx SE

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

349.3 EUR

Average target price

439.3 EUR

Spread / Average Target

+25.77%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ARGENX SE	+1.69%	22.15B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B
LEGEND BIOTECH CORPORATION	-24.71%	8.24B

Bio Therapeutic Drugs